Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme confirms that the newly released CMS proposed rule for the Medicare Drug Price Negotiation Program will have zero to minimal impact on its royalty revenue through at least 2035. The company attributes this favorable outlook to the preservation of orphan drug protections and specific provisions regarding biosimilar entry in the proposed rule under the One Big Beautiful Bill Act. CEO Dr.
Key figures
- Impact projection
- zero to minimal
- Projection horizon
- through at least 2035
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.